Harnessing Value-Based Medicine to Improve Healthcare Efficiency: A Tech Perspective

By João L. Carapinha

October 9, 2023

Value-based medicine, or VBM, is changing healthcare management worldwide by introducing innovative methods to reduce costs and enhance patients’ health.

VBM aims to optimise medical treatments by considering their clinical, social, and financial outcomes, rather than merely reducing costs. One area where the impact of VBM can be observed is in the care of individuals who have suffered from a stroke.

The increasing prevalence of elderly and people with chronic diseases places more strain on healthcare infrastructure. With the increasing affordability of computers and cell phones thanks to technological advancements and economies of scale, it is surprising that the same cannot be said for healthcare. Over the last 20 years, the industry has only experienced a 6% increase in revenue. This is due to skyrocketing prices and poor efficiency, which makes predicting results difficult in the face of rising demand.

Because VBM understands the value of medical care based on how likely it is to make a patient healthier, it removes this waste. It ensures that improving outcomes for patients is ahead of cutting costs. This focus on the patient has led to several global trends, such as:

1. The establishment of policies for value-based pricing and reimbursement.
2. The creation of patient-centric outcomes.
3. The promotion of data-driven operations in healthcare.
4. The rise of artificial intelligence and big data.
5. The shift towards value-based procurement and research.

Due to the need for quick diagnosis and intense long-term rehabilitation after a stroke, a healthcare IT boom has occurred. This has resulted in improved patient management by speeding up communication between healthcare providers. Furthermore, the use of artificial intelligence and large amounts of data could greatly benefit neuroimaging and the assessment of risk.

Despite its excellent results, critics of value-based medicine argue that it can replace trust in doctors with accountability and devalue the caring aspect of healthcare. But medicine’s long-term survival depends on how scientifically sound it becomes.

VBM represents a major shift in healthcare. It solves the problem of low efficiency and rewards patients for sharing their medical data. The future of healthcare delivery depends on providers being able to accurately determine the value of each disease and set up networks that maintain the flow of value.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.